Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis

a technology of extracellular matrix protein and diagnosis, applied in the direction of antibody medical ingredients, peptide/protein ingredients, instruments, etc., can solve the problems of fragmentation and aldehyde-modification of respective matrix proteins, and remain largely unexplored

Inactive Publication Date: 2007-05-10
CARDIOVAX
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a possibility that remains largely unexplored is that reactive aldehydes that are generated during LDL oxidation may not only react with apo B-100 but also with the extracellular matrix proteins to which the LDL is adhered.
If this happens it is likely to result in fragmentation and aldehyde-modification also of the respective matrix protein.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
  • Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis
  • Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009] The present invention in particular relates to the use of fibronectin, tenascin, collagens type I, III, VI and / or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis.

[0010] In a preferred embodiment the fibronectin, tenascin, collagens type I, III, VI and VIII have been modified by malondialdehyde.

[0011] A further preferred embodiment relates to the use of antibodies against glycosylated or aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and VIII produced by immunization or recombinant technique for detection of aldehyde-modified or glycosylated fibronectin, tenascin, collagen type I, III, VI and / or VIII in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques.

[0012] A still further preferred embodiment relates to the use of labelled antibodies against glycosylated or aldehyde-modified fibronectin, tenascin, collagens type I, III, VI and / o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and / or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and / or VIII for prevention and treatment of atherosclerosis.

Description

TECHNICAL FIELD [0001] The present invention relates to the use of certain connective tissue proteins or derivatives thereof for detection of antibodies in plasma and serum to diagnose atherosclerosis, as well as the use of antibodies against such connective tissue proteins or derivatives thereof produced by immunization or recombinant technique for detection of certain connective tissue proteins or derivatives thereof in plasma and serum to diagnose presence of unstable and rupture-prone atherosclerotic plaques. BACKGROUND OF THE INVENTION [0002] Atherosclerosis is a degenerative disease of medium- and large-sized arteries. It is the major cause of acute myocardial infarction, stroke and peripheral artery disease. The first stages of the disease are characterized by accumulation of cholesterol-loaded macrophages forming small fatty streaks on the inside of the arterial wall. Activation of a chronic inflammatory process within these fatty streaks leads to the formation of raised fib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/00G01N33/53A61K38/39A61K39/395A61P9/10G01NG01N33/68
CPCA61K38/39G01N33/6887G01N33/6893A61P9/10
Inventor NILSSON, JAN
Owner CARDIOVAX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com